The European Medicines Regulatory Agency said on Friday that it does not recommend AstraZenece for people with rare bleeding episodes to fight against covida-19, and it is also investigating cases of myocardial inflammation following all coronavirus vaccines.
The European Medicines Agency (EMA) Drug Safety Committee believes that capillary hemorrhage syndrome must be listed as a side effect of the covida-19 AstraZeneca vaccine.
This is a disease that bleeds from the smallest veins to muscles and body cavities, and is characterized by swelling and decreased blood pressure.
After receiving vaccines from AstraZeneca, Pfizer, Moderna and Johnson & Johnson, EMA is also expanding its investigation of myocarditis and pericarditis cases.
Data from the United States and Israel indicate that after young men have higher-than-expected medical problems, a link may be established between myocarditis and pericarditis and mRNA vaccines.